Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity

The BRAF inhibitor (BRAFi) treatment has led to impressive responses in BRAF(V600E) mutation-positive melanomas, but responses are not durable in many patients. As most of the BRAFi escape mechanisms involve ERK reactivation, combinations with MEK inhibitors (MEKi) are currently tested to improve BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadiot, Jules, Hooijkaas, Anna I, Deken, Marcel A, Blank, Christian U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849083/
https://www.ncbi.nlm.nih.gov/pubmed/24348046
http://dx.doi.org/10.2147/OTT.S52552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849083/
https://www.ncbi.nlm.nih.gov/pubmed/24348046
http://dx.doi.org/10.2147/OTT.S52552

Ejemplares similares